|
1
|
Jeyapalan JC and Sedivy JM: Cellular
senescence and organismal aging. Mech Ageing Dev. 129:467–474.
2008.
|
|
2
|
Krtolica A and Campisi J: Cancer and
aging: a model for the cancer promoting effects of the aging
stroma. Int J Biochem Cell Biol. 34:1401–1414. 2002.
|
|
3
|
Lombard DB, Chua KF, Mostoslavsky R, et
al: DNA repair, genome stability, and aging. Cell. 120:497–512.
2005.
|
|
4
|
Jung-Hynes B and Ahmad N: Role of p53 in
the anti-proliferative effects of Sirt1 inhibition in prostate
cancer cells. Cell Cycle. 8:1478–1483. 2009.
|
|
5
|
Yi J and Luo J: SIRT1 and p53, effect on
cancer, senescence and beyond. Biochim Biophys Acta.
1804:1684–1689. 2010.
|
|
6
|
Liu T, Liu PY and Marshall GM: The
critical role of the class III histone deacetylase SIRT1 in cancer.
Cancer Res. 69:1702–1705. 2009.
|
|
7
|
Fang Y and Nicholl MB: Sirtuin 1 in
malignant transformation: friend or foe? Cancer Lett. 306:10–14.
2011.
|
|
8
|
Tseng RC, Lee CC, Hsu HS, et al: Distinct
HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and
adenocarcinoma patients. Neoplasia. 11:763–770. 2009.
|
|
9
|
Deng CX: SIRT1, is it a tumor promoter or
tumor suppressor? Int J Biol Sci. 5:147–152. 2009.
|
|
10
|
Kim JE, Chen J and Lou Z: DBC1 is a
negative regulator of SIRT1. Nature. 451:583–586. 2008.
|
|
11
|
Abdelmohsen K, Pullmann R Jr, Lal A, et
al: Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol
Cell. 25:543–557. 2007.
|
|
12
|
Kim EJ, Kho JH, Kang MR and Um SJ: Active
regulator of SIRT1 cooperates with SIRT1 and facilitates
suppression of p53 activity. Mol Cell. 28:277–290. 2007.
|
|
13
|
Ford J, Jiang M and Milner J:
Cancer-specific functions of SIRT1 enable human epithelial cancer
cell growth and survival. Cancer Res. 65:10457–10463. 2005.
|
|
14
|
Huffman DM, Grizzle WE, Bamman MM, et al:
SIRT1 is significantly elevated in mouse and human prostate cancer.
Cancer Res. 67:6612–6618. 2007.
|
|
15
|
Bradbury C, Khanim FL, Hayden R, et al:
Histone deacetylases in acute myeloid leukaemia show a distinctive
pattern of expression that changes selectively in response to
deacetylase inhibitors. Leukemia. 19:1751–1759. 2005.
|
|
16
|
Kabra N, Li Z, Chen L, et al: SirT1 is an
inhibitor of proliferation and tumor formation in colon cancer. J
Biol Chem. 284:18210–18217. 2009.
|
|
17
|
Yeung F, Hoberg JE, Ramsey CS, et al:
Modulation of NF-kappaB-dependent transcription and cell survival
by the SIRT1 deacetylase. EMBO J. 23:2369–2380. 2004.
|
|
18
|
Tang Y, Zhao W, Chen Y, Zhao Y and Gu W:
Acetylation is indispensable for p53 activation. Cell. 133:612–626.
2008.
|
|
19
|
Wang C, Chen L, Hou X, et al: Interactions
between E2F1 and SirT1 regulate apoptotic response to DNA damage.
Nat Cell Biol. 8:1025–1031. 2006.
|
|
20
|
Stünkel W, Peh BK, Tan YC, et al: Function
of the SIRT1 protein deacetylase in cancer. Biotechnol J.
2:1360–1368. 2007.
|
|
21
|
Brunet A, Sweeney LB, Sturgill JF, et al:
Stress-dependent regulation of FOXO transcription factors by the
SIRT1 deacetylase. Science. 303:2011–2015. 2004.
|
|
22
|
Kobayashi Y, Furukawa-Hibi Y, Chen C, et
al: SIRT1 is critical regulator of FOXO-mediated transcription in
response to oxidative stress. Int J Mol Med. 16:237–243. 2005.
|
|
23
|
An BS, Tavera-Mendoza LE, Dimitrov V, et
al: Stimulation of Sirt1-regulated FoxO protein function by the
ligand-bound vitamin D receptor. Mol Cell Biol. 30:4890–4900.
2010.
|
|
24
|
Hokka D, Maniwa Y, Tane S, et al: Psf3 is
a prognostic biomarker in lung adenocarcinoma. Lung Cancer.
79:77–82. 2013.
|
|
25
|
Satoh N, Maniwa Y, Bermudez VP, Nishimura
K, Nishio W, Yoshimura M, et al: Oncogenic hosphatase Wip1 is a
novel prognostic marker for lung adenocarcinoma patient survival.
Cancer Sci. 102:1101–1106. 2011.
|
|
26
|
Nakai R, Maniwa Y, Tanaka Y, Nishio W,
Yoshimura M, Okita Y, et al: Overexpression of Necl-5 correlates
with unfavorable prognosis in patients with lung adenocarcinoma.
Cancer Sci. 101:1326–1330. 2010.
|
|
27
|
Ke Q and Costa M: Hypoxia-inducible
factor-1 (HIF-1). Mol Pharmacol. 70:1469–1480. 2006.
|
|
28
|
Volm M and Koomägi R: Hypoxia-inducible
factor (HIF-1) and its relationship to apoptosis and proliferation
in lung cancer. Anticancer Res. 20:1527–1533. 2000.
|
|
29
|
Greijer AE and van der Wall E: The role of
hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J
Clin Pathol. 57:1009–1014. 2004.
|
|
30
|
Halliwell B: Oxidative stress and cancer:
have we moved forward? Biochem J. 401:1–11. 2007.
|
|
31
|
Brooks CL and Gu W: How does SIRT1 affect
metabolism, senescence and cancer? Nat Rev Cancer. 9:123–128.
2009.
|
